Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations of future revenues and expenses, forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and change change over time. Factors that could cause actual disputed by disputed by the forward-looking statements or historical experience include risks and uncertainties, including to ensure the failure GenVec and maintaining relationships with employees, risks relating to the early stage of GenVec ‘s product candidates in development, uncertainties related to clinical trials, risks relating to the commercialization, if any, of the proposed product GenVec the candidates, the dependence on the efforts of third parties, dependence on intellectual property rights, and risks that we have the financial resources and access to capital is missing our activities our activities.

Encouraging results from TNFerade Head and Neck Cancer Study presented at ASCOEncouraging data from GenVec ‘ s Phase I clinical trial of TNFerade in patients with head and neck cancer were presented by lead investigator Everett Vokes, University of Chicago, in a poster session at the annual meeting the American Society of Clinical Oncology in Chicago.Ask a new U.S. Study published of journal Cancer reports an troubling trend across the country. Few female is for screening mammography examinations shall be recognized early stage breast.

The widespread adoption of mammographies since the 1980s for screening for women over 40 years in the United States were have been seen by scientists as the primary reason of the reduction in deaths by breast cancer. Between 1987 and 2000 screening was rate of walked 39-70 % among women aged over 40. 15 and her colleagues are worried, like many healthcare professionals, ‘that some of the reported decline in the incidence is some due to the flattening and reduction of of mammographic rates may ‘.